Home Tools
Log in
Cart

Search Result

Search Results for " complement c5 "

16

Compounds

Cat No. Product Name Synonyms Targets
T10863 Complement C5-IN-1 Complement System
Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).
T9915 Eculizumab Complement System
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
T76867 Ravulizumab ALXN1210 Complement System
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity to block complement activation. Ravulizumab can be used fo...
T77022 Gefurulimab
Gefurulimab (ALXN-1720) is a bispecific antibody derived from humans, targeting complement C5 and albumin. It specifically binds to C5, inhibiting its activation [1].
T74431 Cemdisiran
Cemdisiran, a conjugated siRNA with N-acetylgalactosamine (GalNAc), targets the liver to inhibit the production of complement 5 (C5) protein, serving as a potential therapeutic agent for the study of complement-mediated ...
T75106 ARC186
ARC186 is a highly potent aptamer that serves as a complement inhibitor by blocking the convertase-catalyzed activation of C5.
T74551 Avacincaptad pegol sodium
Avacincaptad pegol (ARC1905), an anti-C5 RNA aptamer, prevents the cleavage of complement factor 5 (C5) into fragments C5a and C5b. It is currently under investigation for the treatment of age-related macular degeneratio...
T76276 Zilucoplan
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor, is utilized in the study of immune-mediated necrotising myopathy (IMNM) [1] [2].
T77121 Pozelimab
Pozelimab (REGN3918), a fully human IgG4 monoclonal antibody, is designed to target and bind with high affinity to both C5 and its variants, effectively inhibiting complement-mediated hemolysis. It holds potential for re...
T74552 Non-PEGylated/naked ARC1905
ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched ...
T74550 Cemdisiran, terminal sugar modification-
Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA,...
T77190 Crovalimab
Crovalimab (SKY59; RO7112689) is a novel humanized antibody designed to target C5 in a pH-dependent manner, demonstrating binding affinities (KD) of 15.2 nM and 16.8 μM at pH levels of 7.4 and 5.8, respectively. Addition...
T80083 Zilucoplan TFA RA101495 TFA Complement System
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, serves as a potent inhibitor of complement component 5 (C5). It has applications in the study of immune-mediated necrotising myopathy (IMNM) [1] [2].
T78191 NH2-C6-ARC186 Complement System
NH2-C6-ARC186 is a derivative of the aptamer ARC186, featuring an NH2-C6 moiety that enables coupling to various peptides or molecules. As a potent complement inhibitor, it operates by inhibiting convertase-mediated C5 a...
T77163 Pexelizumab
Pexelizumab (h5G1.1-SC), a humanized scFv monoclonal antibody, targets the C5 complement component, thereby inhibiting apoptosis and leukocyte infiltration. It is utilized in researching cerebral ischemia-reperfusion (IR...
T74699 Avacincaptad pegol
Avacincaptad pegol, a pegylated aptamer, stands out as an effective C5 complement inhibitor capable of mitigating inflammation-induced damage to the retinal pigment epithelium (RPE). This compound is under investigation ...
TargetMol